Johnson and Johnson Ebola Vaccine Program Approved by EU

Read: The study data show that the vaccine program is well-tolerated and can induce a strong and long-lasting immune response to the Genus of the Congolese Ebola viruscompilation of Cocolocal time, Johnson and Johnson announced that its Jansen Pharmaceuticals' dual measurement of the Ebola vaccine, Zabdeno ® (Ad26.ZEBOV) and mvabea ® (MVABNFilo) have been approved by the European Commission (EC) for active immunization to prevent The Democratic Republic of the Congo Ebola virus species caused by individuals 1 years of age and older to contract Ebola virus's worst Ebola outbreak to date occurred in West Africa, infecting nearly 30,000 people and killing more than 11,000 in 2014-2016The world's second most severe Ebola outbreak, recorded in Congo in 2018, has now killed more than 3,000 infections, killed more than 2,000 and killed 65 percentDr Paul Stoffels, Vice Chairman and Chief Scientific Officer ofJohnson and Johnson, said: "The European approval of Jansen's Ebola vaccine programme is a landmark moment, both for our company and in the world's fight against the deadly Ebola virus"This approved Ebola vaccine is the first vaccine to appear on our vaccine line and the first to be developed using the development of Jansen AdVac ®," said DrMathai Mammen, Global Head of Research and Development atJanssenThe same technology is currently being used to develop vaccine candidates for the prevention of SARS-CoV-2, Zika, respiratory syncytial virus (RSV) and human immunodeficiency virus (HIV)Jansen's Ebola vaccine program consists of two doses of the vaccine, the first dose of Ad26.ZEBOV based on a virus vector development®, and the second dose of MVABNFilo, based on the ® technology of Bavarian NordicAdVac ® technology uses adenoviruses as vectors, carrying the genetic code of several Ebola virus proteins to simulate the composition of pathogens and trigger an immune responseAntigens are produced to simulate pathogens and do not cause serious illnessWhen the body encounters antigens, it fights against the progenitor's long-lasting body fluid immunity and cellular immune response by producing immune cells and antibodiesIn the future, if the human body encounters an actual pathogen, it will be able to respond more quickly and effectively to prevent pathogens from causing diseaseThe MVA-BN ® technology is a further detoxified version using the modified Ankarapox virus (MVA), which cannot be replicated in vaccinated individuals, meaning that the virus cannot be transmitted in vaccinated people, and induces a strong cellular activity (CTL) and body fluid (antibody) immune response, as well as stimulating responses in individuals that already have vaccine immunity programme is specifically designed to induce long-term immunity to the Ebola virus in adults and children over 1 year of age It will therefore be used for preventive vaccination in countries most likely to experience outbreaks, as well as for other high-risk groups Jansen has published its Clinical Study of Preventive Ebola Vaccine Program Phase 1 in the Journal of the American Medical Association and the Journal of Infectious Diseases, and published the results of 11 clinical studies in 1, 2 and 3, 2019 at the European Conference on Clinical Microbiology and Infectious Diseases (ECCMID), which assessed the safety and progenition of the vaccine program in more than 6,500 children and adults aged and over in the United States, Europe and Africa these studies show that the vaccine program is well-tolerated and can induce a strong and long-lasting immune response to the Genus of the Congolese Ebola virus The protective effect of the vaccine program was demonstrated by combining clinical immunogenicity results with the efficacy and immunogenicity data obtained in non-human primates May 2019, the WHO Strategic Advisory Group on Immunization (SAGE) recommended the use of the Ebola vaccine programme as an effort to contain an outbreak of Ebola virus transmission in congo At the same time, as a measure to prevent the spread of the Ebola virus outside the affected areas To date, more than 50,000 people have been vaccinated in Congo and Rwanda About 60,000 people, including clinical studies, have been vaccinated against the vaccine At present, Jansen is actively preparing to seek the U.S FDA listing application Reference Source: Johnson and Johnson Announces European Commission Approval for Janssen's Ebola Vaccine